Scinovex
review Open AccessTop 1% cited

Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects

British Journal of Pharmacology · 2011 · Vol. 163(7) · pp. 1344–1364
Ethan B. Russo

Abstract

Tetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964, when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic contributions of cannabidiol to cannabis pharmacology and analgesia have been scientifically demonstrated. Other phytocannabinoids, including tetrahydrocannabivarin, cannabigerol and cannabichromene, exert additional effects of therapeutic interest. Innovative conventional plant breeding has yielded cannabis chemotypes expressing high titres of each component for future study. This review will explore another echelon of phytotherapeutic agents, the cannabis terpenoids: limonene, myrcene, α-pinene, linalool, β-caryophyllene, caryophyllene oxide, nerolidol and phytol. Terpenoids share a precursor with phytocannabinoids, and are all flavour and fragrance components common to human diets that have been designated Generally Recognized as Safe by the US Food and Drug Administration and other regulatory agencies. Terpenoids are quite potent, and affect animal and even human behaviour when inhaled from ambient air at serum levels in the single digits ng·mL(-1) . They display unique therapeutic effects that may contribute meaningfully to the entourage effects of cannabis-based medicinal extracts. Particular focus will be placed on phytocannabinoid-terpenoid interactions that could produce synergy with respect to treatment of pain, inflammation, depression, anxiety, addiction, epilepsy, cancer, fungal and bacterial infections (including methicillin-resistant Staphylococcus aureus). Scientific evidence is presented for non-cannabinoid plant components as putative antidotes to intoxicating effects of THC that could increase its therapeutic index. Methods for investigating entourage effects in future experiments will be proposed. Phytocannabinoid-terpenoid synergy, if proven, increases the likelihood that an extensive pipeline of new therapeutic products is possible from this venerable plant. http://dx.doi.org/10.1111/bph.2011.163.issue-7.

Cannabis and Cannabinoid ResearchGABA and Rice ResearchBiochemical Analysis and Sensing TechniquesCannabidiolTerpenoidCannabisPharmacologyEffects of cannabisDronabinolHallucinogenCannabinoidChemistryMedicine

MeSH terms

AnimalsCannabisDrug SynergismHumansPhytotherapyTerpenesDronabinol

Funding

  • GW Pharmaceuticals
Citations
1,488
FWCI
18.44
field-weighted impact
References
292
Percentile
100%
vs. same field & year
Citations per year
Cited by
Cannabidiol (CBD) and its analogs: a review of their effects on inflammation
Bioorganic & Medicinal Chemistry · 2015 · 563 citations
Pharmaceutical and biomedical analysis of cannabinoids: A critical review
Journal of Pharmaceutical and Biomedical Analysis · 2017 · 246 citations
Cannabinoids and Pain: New Insights From Old Molecules
Frontiers in Pharmacology · 2018 · 356 citations
Cannabis sativa: The Plant of the Thousand and One Molecules
Frontiers in Plant Science · 2016 · 1,499 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.